sponsored
PatientsVille.com Logo

PatientsVille

Linezolid Medical Research Studies

Up-to-date List of Linezolid Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Linezolid Medical Research Studies

Rank Status Study
1 Unknown  Pharmacokinetics of Linezolid in Children With Cystic Fibrosis
Condition: Cystic Fibrosis
Intervention: Drug: Linezolid
Outcome Measures: To determine the pharmacokinetic profile of IV (intravenous) and PO (oral) formulations of Linezolid among children with cystic fibrosis and establish a dose regimen that will be safe and effective.;   to characterize the clinical response of children with pulmonary exacerbations (increase in the severity of the patient's lung symptoms) associated with methicillin resistant Staphylococcus aureus (MRSA) to treatment with Linezolid
2 Recruiting Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia
Condition: Pneumonia
Intervention: Drug: Linezolid
Outcome Measures: Pharmacokinetics/-dynamics of Linezolid in blood samples: T>MIC of 100.;   Pharmacokinetics/-dynamics of Linezolid in urine samples.
3 Recruiting Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin Infections
Conditions: Skin Diseases, Bacterial;   Abscess
Interventions: Biological: Linezolid;   Biological: Clindamycin
Outcome Measures: The presence of Staphylococcus aureus after treatment with Linezolid versus clindamycin;   Clinical response of skin infections to treatment;   The type of of Staphylococcus aureus present at the diagnosis will be compared to the type of Staphylococcus aureus present after treatment
4 Recruiting Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Condition: Bacterial Infections
Interventions: Drug: Tedizolid (BAY119-2631);   Drug: Placebo Tedizolid (BAY119-2631);   Drug: Linezolid;   Drug: Placebo Linezolid
Outcome Measures: Early Clinical Response;   Clinical response at the End of Treatment (EOT) Visit;   Investigator's assessment of clinical success at the Post Therapy Evaluation (PTE) Visit;   Investigator's assessment of clinical response at the 48-72 hours visit;   Investigator's assessment of clinical response at the 7 day visit;   Change from baseline in the pain scores;   Number of participants with adverse events as a measure of safety and tolerability
5 Recruiting TR-701 FA vs Linezolid for the Treatment of Nosocomial Pneumonia
Condition: Pneumonia
Interventions: Drug: TR-701 FA IV;   Drug: Linezolid
Outcome Measures: All Cause Mortality;   All Cause Mortality, Micro-ITT;   Clinical Response;   All Cause Mortality, MSSA/MRSA;   Clinical Response, MSSA/MRSA
6 Unknown  Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia
Conditions: Methicillin-resistant Staphylococcus Aureus;   Pneumonia, Ventilator-Associated
Intervention: Drug: Imipenem/cilastatin
Outcome Measures: MRSA eradication;   mortality
7 Recruiting Randomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole Plus Rifampicin With a Regimen of Linezolid in the Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection
Condition: MRSA Infection
Interventions: Drug: trimethoprim-sulfamethoxazole (TMP-SMX);   Drug: Linezolid;   Drug: Rifampicin
Outcome Measures: Bacteriological and clinical cure;   Treatment costs
8 Not yet recruiting Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis
Condition: Pulmonary Tuberculosis Without Resistance to Rifampicin
Interventions: Drug: Linezolid;   Drug: Ethambutol
Outcome Measures: Sputum culture conversion rate on liquid media;   Sputum culture conversion rate on solid media;   Time to sputum culture conversion (liquid and solid media);   Cure rate;   Treatment success rate
9 Unknown  Vitamin B6 on Relieving Linezolid-associated Cytopenias
Conditions: Cytopenias;   Erythropenia (Diagnosis)
Intervention:
Outcome Measure:
10 Recruiting Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection
Condition: Hip Prosthetic Joint Infection
Interventions: Drug: VANCOMYCIN;   Drug: CEFTRIAXONE;   Drug: CLINDAMYCIN;   Drug: SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE);   Drug: FLUOROQUINOLONE;   Drug: Linezolid;   Drug: RIFAMPIN
Outcome Measures: Clinical cure rate;   Cure rate
11 Recruiting Study of Concentration and Antimicrobial Activity of Antibiotics Used for Catheter-Related Infections
Conditions: Catheter-related Bloodstream Infection.;   Bacteremia.
Interventions: Drug: Administration of vancomycin in antibiotic lock solution;   Drug: Administration of teicoplanin in antibiotic lock solution;   Drug: Administration of Linezolid in antibiotic lock solution;   Drug: Administration of daptomycin in antibiotic lock solution;   Drug: Administration of tigecycline in antibiotic lock solution
Outcome Measures: Antibiotic concentration in catheter-lock solutions at the end of day 1.;   Antibiotic concentration in catheter-lock solutions at the end of day 3.;   Antibiotic concentration in catheter-lock solutions at the end of day 5.;   Antibiotic concentration in catheter-lock solutions at the end of day 7.;   Antibiotic concentration in catheter-lock solutions at the end of day 10.;   Antimicrobial activity of antibiotics in lock solutions at the end of lock time assigned.;   Anticoagulant activity of heparin in antibiotic lock solutions at the end of lock time assigned.
12 Unknown  Study of Antibiotics in Cerebrospinal Fluid Following Intravenous Injection
Condition: Neurosurgery
Interventions: Drug: Vancomycin;   Drug: Teicoplanin;   Drug: Linezolid
Outcome Measure: Concentration of antibiotics in cerebrospinal fluid
13 Recruiting Urinary KIM-1 After Vancomycin or Linezolid Administration
Condition: Acute Kidney Injury
Intervention:
Outcome Measure: Urinary KIM-1 concentrations
14 Recruiting A Phase III Study to Evaluate the Efficacy and Safety of BAY 1192631 in Japanese Patients With MRSA Infections (SSTI and SSTI-related Bacteremia).
Condition: Skin Diseases, Infectious
Interventions: Drug: Tedizolid(BAY1192631);   Drug: Linezolid
Outcome Measures: Clinical response at Test of Cure (TOC);   Microbiological response at Test of Cure (TOC);   Clinical response at End of Treatment(EOT);   Microbiological response at End of Treatment(EOT);   Population Pharmacokinetics parameters and Pharmacokinetics/Pharmacodynamics parameters characterized by AUC/MIC;   Population Pharmacokinetics parameters and Pharmacokinetics / Pharmacokinetics parameters characterised by Cmax/MIC;   Number of participants with adverse events as a measure of safety and tolerability
15 Recruiting Staphylococcus Aureus Bacteremia Antibiotic Treatment Options
Condition: Staphylococcus Aureus Bloodstream Infection
Interventions: Drug: Trimethoprim-Sulfamethoxazole;   Drug: Clindamycin;   Drug: Linezolid;   Drug: Flucloxacillin;   Drug: Cloxacillin;   Drug: Vancomycin;   Drug: Daptomycin;   Drug: Cefazolin
Outcome Measures: SAB-related complications;   Length of hospital stay;   Survival;   Complications of intravenous therapy
16 Not yet recruiting Patients Response to Early Switch To Oral:Osteomyelitis Study
Condition: Osteomyelitis
Interventions: Drug: oral antibiotics;   Procedure: intravenous antibiotics
Outcome Measures: Clinical Failures;   Evaluation of adverse events related to the use of antibiotics;   Cost of care from the hospital perspective
17 Unknown  Early Medical Thoracoscopy Versus Simple Chest Tube Drainage in Complicated Parapneumonic Effusion and Pleural Empyema
Conditions: Complicated Parapneumonic Effusion;   Pleural Empyema
Interventions: Procedure: Medical thoracoscopy;   Procedure: Simple chest tube drainage
Outcome Measures: Medical cure without secondary Intervention;   Death;   Duration of hospital stay;   Radiological outcome;   Duration of drainage;   Total amount of drainage fluid;   Estimated cost;   Adverse events;   Pleural pharmacokinetics of Linezolid
18 Recruiting Drug Monitoring of Antibiotics in Critical Care Patients
Conditions: ARDS;   Sepsis
Intervention:
Outcome Measures: Variability of antibiotic serum concentrations in critically ill patients;   correlate these serum concentrations with clinical and laboratory outcome Correlate serum concentrations with clinical and laboratory outcome parameters
19 Recruiting Efficacy and Safety of Garamycin® Sponge (Gentamicin-Collagen Sponge) in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection
Condition: Diabetic Foot Ulcer
Interventions: Drug: Garamycin Sponge (Gentamicin-Collagen sponge);   Drug: Systemic Antibiotic
Outcome Measures: The percent of patients with a clinical outcome of "clinical cure" at the test of cure visit;   Percent of patients with a clinical outcome of "clinical cure" at the end of treatment visit;   Percent of patients with a clinical response;   Time to clinical cure;   The percent of patients with baseline pathogen eradication

These studies may lead to new treatments and are adding insight into Linezolid etiology and treatment.

A major focus of Linezolid research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Linezolid